Pacira Pharmaceuticals buy Barclays PLC
Start price
08.05.24
/
50%
€26.80
Target price
08.05.25
€35.35
Performance (%)
-50.37%
Price
27.09.24
€12.90
Summary
This prediction is currently active. Massive losses of -50.37% have been the result for the BUY prediction by Barclays_PLC. This prediction currently runs until 08.05.25. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | -1.527% | -1.527% |
iShares Core DAX® | 3.523% | 3.763% |
iShares Nasdaq 100 | 1.026% | 2.380% |
iShares Nikkei 225® | -0.063% | 0.000% |
iShares S&P 500 | 0.557% | 2.222% |
Comments by Barclays_PLC for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $40.00 to $38.00. They now have an "overweight" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Barclays_PLC for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€26.20
23.10.23
23.10.23
€53.51
23.10.24
23.10.24
-51.53%
27.09.24
27.09.24